GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ICCM
IceCure Medical is an Israeli company that has developed cryoablation (freezing) technology for destroying tumors. Its stock price is a bet that its minimally invasive method will become a popular alternative to surgery.
Share prices of companies in the market segment - Therapeutic medical equipment
IceCure Medical has developed cryoablation (freezing) technology that destroys benign and malignant tumors, offering a minimally invasive alternative to surgery. We've classified it in the "Therapeutic Medical Equipment" segment. The chart below shows the overall dynamics of the minimally invasive medical device sector.
Broad Market Index - GURU.Markets
IceCure Medical is an Israeli company that has developed cryoablation (freezing) technology for minimally invasive tumor destruction. Its innovative technology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how IceCure compares to it.
Change in the price of a company, segment, and market as a whole per day
ICCM - Daily change in the company's share price ICCM
For IceCure Medical Ltd., a developer of cryoablation systems, daily volatility reflects sensitivity to regulatory approvals and the adoption of the technology in oncology. This metric is an important element in analyzing companies in the MedTech sector.
Daily change in the price of a set of shares in a market segment - Therapeutic medical equipment
For IceCure Medical Ltd., a developer of cryoablation systems, daily volatility reflects sensitivity to regulatory approvals and the adoption of the technology in oncology. This metric is an important element in analyzing companies in the MedTech sector.
Daily change in the price of a broad market stock, index - GURU.Markets
IceCure Medical develops cryoablation technology—the freezing of tumors. It's a minimally invasive approach to oncology. The company's success depends on the acceptance of its technology by doctors and hospitals. Its stock price fluctuations reflect progress in the fight against cancer, adding a new dimension of medical innovation to the overall market momentum, visible on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ICCM
IceCure Medical Ltd's year-over-year performance is a story of the commercialization of its cryoablation technology. Its market capitalization growth over the past 12 months reflects its success in securing regulatory approvals and the growing number of hospitals using its system for freezing and destroying tumors, a minimally invasive alternative to surgery.
Annual dynamics of market capitalization of the market segment - Therapeutic medical equipment
IceCure Medical Ltd. is an Israeli medical company that developed cryoablation technology for non-invasive tumor destruction. The chart shows how its innovative technology, its growing adoption, and competition with traditional surgical methods are driving its rapid growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
IceCure, with its cryoablation technology for cancer treatment, is a growth story in medicine. Its stock price is driven not by the economy, but by the speed of adoption by doctors and the insurance system. The chart reflects the potential of this breakthrough technology in the vast oncology market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ICCM
IceCure Medical produces cryoablation systems for tumor treatment. Its monthly growth reflects progress in commercializing its technology. News of regulatory approvals (especially the FDA) and the growing number of procedures performed using its system are the main drivers.
Monthly dynamics of market capitalization of the market segment - Therapeutic medical equipment
IceCure Medical has developed cryoablation (freezing) technology for destroying tumors without surgery. The company is commercializing its systems for treating breast cancer and other tumors. The medical device sector's performance reflects the overall interest in minimally invasive technologies, which is a favorable trend for IceCure.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
IceCure Medical develops cryoablation (freezing) technology for tumor destruction. As a medical device manufacturer, the company relies on regulatory approval and clinical implementation of its method. Its stock price is weakly linked to economic cycles and reflects progress in commercializing its technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ICCM
IceCure Medical, an Israeli company that developed cryoablation (freezing) technology for cancer treatment, whose weekly stock price reflects demand for minimally invasive oncology procedures. Regulatory approvals and clinical trial data drive highly volatile short-term trends.
Weekly dynamics of market capitalization of the market segment - Therapeutic medical equipment
IceCure Medical has developed cryoablation technology for non-invasive tumor destruction. This chart compares its weekly performance with the medical equipment sector and helps understand how the market views its innovative treatment method against traditional surgical approaches and other technologies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
IceCure Medical is a medical equipment company. The healthcare sector is considered defensive. The chart will help you assess whether ICCM shares are acting like a defensive asset or, like a small company, are more volatile.
Market capitalization of the company, segment and market as a whole
ICCM - Market capitalization of the company ICCM
IceCure Medical's chart is a financial map of the fight against cancer using cold. The market capitalization of this Israeli company, whose cryoablation technology freezes and destroys tumors, reflects the demand for minimally invasive treatments. Its dynamics are a barometer of its clinical success and the approvals it receives for its system worldwide.
ICCM - Share of the company's market capitalization ICCM within the market segment - Therapeutic medical equipment
IceCure Medical's market share in the therapeutic equipment sector reflects its leadership in cryoablation—tumor freezing. Its market share is driven by the adoption of its minimally invasive cancer treatment technology in hospitals worldwide as an alternative to surgery.
Market capitalization of the market segment - Therapeutic medical equipment
IceCure Medical is developing a minimally invasive system for freezing and destroying tumors. The chart below shows the overall market capitalization of the entire medical equipment sector. Its growth reflects the trend toward more gentle cancer treatments and alternatives to surgery.
Market capitalization of all companies included in a broad market index - GURU.Markets
IceCure Medical has developed cryoablation (freezing) technology for non-invasive tumor destruction. Its market capitalization is based on the potential of this technology in oncology. The chart below shows the economic weight of companies offering alternatives to surgery.
Book value capitalization of the company, segment and market as a whole
ICCM - Book value capitalization of the company ICCM
IceCure Medical, a manufacturer of cryoablation systems, derives its book value from its production capacity and inventory. The chart below shows the underlying financial position of its business. Its growth reflects investments in production and expanded sales of its minimally invasive tumor treatment technology.
ICCM - Share of the company's book capitalization ICCM within the market segment - Therapeutic medical equipment
IceCure Medical develops cryoablation systems for tumor treatment. Certified manufacturing facilities are required to produce these medical devices. The asset share chart shows how the company is investing in building its own physical infrastructure.
Market segment balance sheet capitalization - Therapeutic medical equipment
IceCure Medical is a manufacturer of cryoablation equipment. Its strength lies in its R&D center and production lines, where its unique tumor freezing probes are created. It's a capital-intensive technology business. The chart below illustrates how dependent the entire medical device industry is on manufacturing capabilities.
Book value of all companies included in the broad market index - GURU.Markets
IceCure Medical's assets include manufacturing facilities and patents for a cryoablation system that destroys tumors using freezing. Its book value reflects the capital invested in this minimally invasive technology, which offers an alternative to surgical tumor removal.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ICCM
IceCure Medical develops cryoablation (freezing) systems for tumor destruction. Its value lies in its ProSense technology, a minimally invasive alternative to surgery. The chart shows how investors view the technology's adoption by physicians and its potential in the oncology market.
Market to book capitalization ratio in a market segment - Therapeutic medical equipment
IceCure Medical has developed a cryoablation (freezing) system for destroying tumors. It is a medical technology company. The chart shows how the market views its minimally invasive technology and its potential to become an alternative to surgery.
Market to book capitalization ratio for the market as a whole
IceCure Medical develops and markets minimally invasive cryoablation (freezing) systems for tumor treatment. The chart shows how the market values this alternative to surgery. The premium its market capitalization has on its assets reflects the potential for its technology to become a standard of care for certain types of cancer due to its reduced invasiveness.
Debts of the company, segment and market as a whole
ICCM - Company debts ICCM
IceCure Medical developed cryoablation (freezing) technology for tumor destruction. Its debt burden may reflect investments in clinical research to expand indications and in establishing a global distribution network for its minimally invasive oncology technology.
Market segment debts - Therapeutic medical equipment
IceCure Medical has developed cryoablation (freezing) technology for non-invasive tumor destruction. It is a promising alternative to surgery. This chart shows the financial standards for the medical device sector, where companies raise capital to conduct clinical trials proving the efficacy and safety of their technology to obtain regulatory approval.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ICCM
IceCure Medical develops and markets cryoablation systems—minimally invasive tumor freezing. Bringing new medical equipment to the global market requires significant investment. This chart shows how the company uses debt to finance production, clinical research, and marketing. This reflects its growth strategy and the risks it faces.
Market segment debt to market segment book capitalization - Therapeutic medical equipment
The development of cryoablation (freezing) systems for cancer treatment, like IceCure Medical's, is a minimally invasive alternative to surgery. This chart reflects the debt burden in the medical device sector. It allows one to assess how the Israeli company is financing the globalization of its unique technology and competing with other tumor treatment methods.
Debt to book value of all companies in the market
IceCure Medical developed cryoablation technology for freezing tumors. Bringing new medical devices to market requires significant investment in marketing and clinical research. The chart below shows how their leveraged strategy compares to the medical device market.
P/E of the company, segment and market as a whole
P/E - ICCM
This chart shows the valuation of IceCure Medical, a company that produces cryoablation (freezing) systems for tumors. For a medical technology company, this metric reflects investors' faith in its minimally invasive technology as an alternative to surgery for cancer treatment.
P/E of the market segment - Therapeutic medical equipment
This chart shows the average valuation for the therapeutic medical device industry, where IceCure Medical operates. This metric reflects how investors generally view the growth and innovation prospects in this industry. It helps understand whether the market values IceCure's technology above or below competitors' solutions.
P/E of the market as a whole
IceCure Medical has developed cryoablation (freezing) technology for the non-invasive destruction of tumors. This technology is used to treat breast, kidney, and other cancers. This chart shows interest in new medical technologies. It helps understand whether the market sees cryoablation as a viable alternative to surgery and how it views the prospects for widespread adoption of IceCure's technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ICCM
IceCure Medical has developed cryoablation (freezing) technology for the minimally invasive destruction of benign and malignant tumors, particularly breast cancer. The company's future depends on the widespread adoption of its technology. This chart reflects investor expectations regarding its potential as an alternative to surgery for certain tumor types.
%20P%2FE%20ICCM&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ICCM&v=1772583136667 "Chart of the company's future (projected) P/E ICCM")
Future (projected) P/E of the market segment - Therapeutic medical equipment
IceCure Medical has developed the ProSense system for cryoablation (freezing) of tumors. This minimally invasive technology is used to treat breast, kidney, and other cancers. The chart shows expectations for the medical equipment sector, helping to understand how the market views this alternative to traditional surgery.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Therapeutic-medical-equipment&v=1772583136685 "Future (projected) P/E graph of the market segment - Therapeutic medical equipment")
Future (projected) P/E of the market as a whole
IceCure Medical has developed a cryoablation system for minimally invasive tumor destruction by freezing. This technology is used to treat breast, kidney, and lung cancer. This overall forecast reflects the healthcare system's readiness for innovation. Optimism in the market suggests that clinics will increasingly adopt new, less invasive treatments like IceCure's.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772583136711 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ICCM
IceCure Medical has developed a minimally invasive cryoablation (freezing) system for tumor destruction. This chart reflects the commercialization of its technology. Revenue growth depends on the adoption of its system in oncology practices for the treatment of breast, kidney, and lung cancer as an alternative to surgery.
Profit of companies in the market segment - Therapeutic medical equipment
ParaZero Technologies Ltd. produces parachute-based safety systems for drones. The company's profitability is growing alongside stricter drone safety regulations. This chart shows how the development of a new industry (drones) is creating demand for safety-enhancing technologies, opening up new markets and growth opportunities.
Overall market profit
IceCure Medical has developed cryoablation technology for the non-invasive destruction of tumors using freezing. The company's system is used to treat breast, kidney, and other cancers. IceCure's growth depends on the adoption of its minimally invasive technology in hospitals worldwide as an alternative to surgery.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ICCM
IceCure Medical has developed a minimally invasive cryoablation (freezing) system for the destruction of tumors, particularly breast cancer. The company's revenue forecast depends on the adoption of its technology as an alternative to surgery. This chart shows analysts' expectations for growth in the minimally invasive oncology market.
%20profit%20of%20the%20company%20ICCM&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ICCM&v=1772583136885 "Graph of future (projected) profit of the company ICCM")
Future (predicted) profit of companies in the market segment - Therapeutic medical equipment
IceCure Medical has developed the ProSense® system for cryoablation (freezing) of tumors, including breast, kidney, and lung cancer. It is a minimally invasive alternative to surgical removal. This graph shows profitability forecasts for the medical device sector. It reflects the growing demand for organ-preserving and less invasive cancer treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Therapeutic-medical-equipment&v=1772583136927 "Graph of future (predicted) profits of companies in a market segment - Therapeutic medical equipment")
Future (predicted) profit of the market as a whole
IceCure Medical develops and markets minimally invasive cryoablation (freezing) systems for tumor destruction. Demand for its technology depends on its clinical effectiveness and hospital budgets. This revenue projection chart provides an overview of the overall economic environment that influences medical institutions' ability to purchase new equipment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772583137007 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ICCM
IceCure Medical has developed and markets the ProSense® cryoablation system, which uses liquid nitrogen to destroy tumors (both malignant and benign) by freezing them. The chart shows how investors evaluate sales of this minimally invasive alternative to surgical tumor removal.
P/S market segment - Therapeutic medical equipment
IceCure Medical Ltd. is an Israeli company that developed the ProSense® minimally invasive cryoablation system for destroying tumors by freezing them. This technology is used to treat breast, kidney, and lung cancer. This chart shows the average rating for the sector, allowing you to assess how the market values IceCure's innovative technology.
P/S of the market as a whole
IceCure Medical has developed a minimally invasive cryoablation (freezing) technology for tumor destruction. The ProSense system is used to treat breast, kidney, and other cancers. This chart helps estimate the market premium the company is willing to pay for its revenue, offering an innovative and gentle alternative to surgery.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ICCM
IceCure Medical has developed a minimally invasive cryoablation (freezing) technology for the destruction of benign and malignant tumors. This chart shows how investors estimate the company's future revenue. It reflects expectations for the implementation of its ProSense system in hospitals as an alternative to surgical tumor removal.
%20P%2FS%20ICCM&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ICCM&v=1772583137420 "The graph of the company's future (projected) P/S ICCM")
Future (projected) P/S of the market segment - Therapeutic medical equipment
IceCure Medical has developed the ProSense® system, which uses cryoablation (freezing) to destroy benign and malignant tumors without surgery. The graph shows how the market estimates IceCure's future sales, reflecting the growing demand for minimally invasive cancer treatments.
%20P%2FS%20market%20segment%20graph%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Therapeutic-medical-equipment&v=1772583137522 "Future (projected) P/S market segment graph - Therapeutic medical equipment")
Future (projected) P/S of the market as a whole
The overall economic revenue forecast depends on innovations in minimally invasive cancer treatment. IceCure Medical, with its cryoablation (tumor freezing) technology, offers patients an alternative to surgery. The growing use of their system for breast, kidney, and lung cancer treatment demonstrates how technology is making treatment more gentle and accessible.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772583137660 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ICCM
IceCure Medical has developed a minimally invasive cryoablation (freezing) system for tumor destruction. The company generates revenue from sales of its ProSense system and disposable probes to hospitals and clinics worldwide. This chart shows how this innovative cancer treatment technology is being applied in clinical practice.
Sales of companies in the market segment - Therapeutic medical equipment
IceCure Medical has developed a minimally invasive cryoablation (freezing) technology for destroying tumors without surgery. This chart shows total revenue in the therapeutic medical equipment sector. It reflects the growing demand for organ-preserving and tissue-sparing cancer treatments, where IceCure technology offers an effective alternative to surgery.
Overall market sales
IceCure Medical is an Israeli company that has developed cryoablation (freezing) technology for minimally invasive tumor destruction. Its ProSense system is used to treat breast, kidney, and other cancers. Demand depends on the implementation of this technology in hospitals. This overall economic situation affects clinics' budgets for purchasing innovative equipment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ICCM
IceCure Medical has developed the ProSense® cryoablation system, which uses liquid nitrogen to destroy tumors without surgery. The company's growth depends on the implementation of this technology. The graph shows analyst revenue expectations, reflecting their sales forecasts for this minimally invasive cancer treatment device.
%20sales%20of%20the%20company%20ICCM&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ICCM&v=1772583137865 "Schedule of future (projected) sales of the company ICCM")
Future (projected) sales of companies in the market segment - Therapeutic medical equipment
IceCure Medical developed the ProSense® system, which uses cryoablation (freezing) to destroy benign and malignant tumors without surgery. This chart shows projected sales for the entire therapeutic medical device sector, reflecting overall trends in minimally invasive oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Therapeutic-medical-equipment&v=1772583137915 "Schedule of future (projected) sales of companies in the market segment - Therapeutic medical equipment")
Future (projected) sales of the market as a whole
IceCure Medical has developed a minimally invasive cryoablation (freezing) system for tumor destruction. Demand for its technology depends on its implementation in clinical practice. This overall economic activity schedule influences the capital budgets of hospitals deciding whether to purchase new high-tech medical equipment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772583137985 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ICCM
IceCure Medical has developed a cryoablation system for non-invasive tumor destruction using freezing. This metric reflects the commercialization of its medical technology. It shows how successfully the company converts revenue from its systems into net profit, which depends on the implementation of its method in clinics worldwide.
Market segment marginality - Therapeutic medical equipment
IceCure Medical develops and markets minimally invasive cryoablation (freezing) systems for tumor treatment. Profitability is determined by sales of its system and consumables. This metric demonstrates the operational effectiveness of this therapeutic technology compared to other oncology treatments.
Market marginality as a whole
IceCure Medical has developed a minimally invasive cryoablation (freezing) system for tumor destruction. Their technology is used to treat breast, kidney, and lung cancer. The company's growth depends on the implementation of their system in hospitals. This overall profitability impacts them through healthcare system budgets for the purchase of innovative medical equipment.
Employees in the company, segment and market as a whole
Number of employees in the company ICCM
IceCure Medical develops and markets minimally invasive cryoablation systems for freezing and destroying tumors. This chart shows the medical technology company's growth. The expansion of its engineering team, as well as sales and clinical support specialists, is directly related to the expansion of its technology worldwide.
Share of the company's employees ICCM within the market segment - Therapeutic medical equipment
IceCure Medical has developed the ProSense® cryoablation system, which destroys tumors by freezing them. This chart shows the percentage of engineers and clinicians the company attracts in the minimally invasive oncology niche. Its team offers an alternative to surgical tumor removal.
Number of employees in the market segment - Therapeutic medical equipment
IceCure Medical Ltd. is an Israeli company that developed cryoablation (freezing) technology for minimally invasive tumor destruction. This chart shows overall employment in the therapeutic medical equipment sector. It illustrates the growing demand for alternative treatments to surgery that are less traumatic for patients.
Number of employees in the market as a whole
IceCure Medical developed cryoablation (freezing) technology to destroy tumors without surgery. This minimally invasive procedure is used to treat cancer. This employment chart reflects the growth of the medical technology sector, where innovators like IceCure are creating jobs for engineers, physicians, and medical equipment sales professionals.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ICCM (ICCM)
IceCure Medical Ltd produces tumor cryoablation (freezing) systems, offering a minimally invasive alternative to surgery. This chart illustrates the company's high technological expertise. High capitalization per employee is typical for manufacturers of complex medical equipment, where value is derived from patents and know-how rather than a large staff.
%20of%20the%20company%20ICCM%20(ICCM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ICCM-ICCM&v=1772583138141 "Chart of market capitalization per employee (in thousands of dollars) of the company ICCM (ICCM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
IceCure Medical has developed cryoablation (freezing) technology for tumor destruction. This innovative medical device reflects the market's appreciation for their minimally invasive technology. Their high market capitalization per employee suggests that their patents and know-how create a significant competitive advantage and growth potential in the oncology market.
%20by%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Therapeutic-medical-equipment&v=1772583138189 "Market capitalization per employee (in thousands of dollars) by market segment - Therapeutic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
IceCure Medical Ltd. has developed cryoablation (freezing) technology for tumor destruction. It's a medical device company. Its employee rating reflects the value of its minimally invasive technology, which offers an alternative to surgery for certain types of cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772583138272 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ICCM (ICCM)
IceCure Medical (ICCM) is an Israeli medical technology company. They produce the ProSense system, which uses cryoablation (extreme cold) to destroy tumors (breast and kidney cancer). They are in the commercial stage. This graph shows how efficiently their team generates net profit (or loss) from sales of these systems.
%20Chart%20ICCM%20(ICCM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ICCM-ICCM&v=1772583138352 "Company Profit Per Employee (in thousands of dollars) Chart ICCM (ICCM)")
Profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
IceCure Medical has developed a tumor freezing technology (cryoablation). This graph is a benchmark in the medical equipment sector. ICCM's effectiveness depends on successful sales of their systems and, more importantly, the growing revenue stream from disposable probes. This "razor and blades" model allows for increasing profits per employee over time.
%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Therapeutic-medical-equipment&v=1772583138399 "Chart of profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
IceCure Medical (ICCM) has developed the ProSense system, which uses cryoablation (extreme cold) to destroy tumors (such as breast cancer) without surgery. This innovative medical device reflects the success of their R&D and sales teams in commercializing this minimally invasive technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772583138450 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ICCM (ICCM)
This chart for IceCure Medical, a developer of a cryoablation system for tumor treatment, shows the commercialization of its technology. The growth in revenue per employee reflects the growing adoption of its minimally invasive cancer cell freezing method in hospitals worldwide.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ICCM-ICCM&v=1772583138543 "Sales chart per company employee ICCM (ICCM)")
Sales per employee in the market segment - Therapeutic medical equipment
IceCure Medical develops and markets systems for tumor cryoablation (freezing), particularly for breast cancer. It's a minimally invasive medical technology company. This metric reflects the average revenue per employee for the segment. It helps evaluate how productive IceCure's team is in R&D and sales of its equipment compared to competitors.
Sales per employee for the market as a whole
IceCure Medical (ICCM) is an Israeli company that developed a technology for cryoablation (freezing) of tumors using liquid nitrogen (the ProSense® system). This metric reflects their commercial success. The growth in revenue per employee indicates that their minimally invasive technology (devices and probes) is finding increasing application in oncology.
Short shares by company, segment and market as a whole
Shares shorted by company ICCM (ICCM)
IceCure Medical is developing a cryoablation (freezing) system for the treatment of tumors, including breast cancer, as a minimally invasive alternative to surgery. This chart reflects investors' bets that its technology will fail to prove its superiority over standard surgery and will not be widely adopted by physicians.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ICCM-ICCM&v=1772583138726 "Short Shares Chart for the Company ICCM (ICCM)")
Shares shorted by market segment - Therapeutic medical equipment
IceCure Medical (ICCM) is an Israeli company that has developed a cryoablation (cold destruction) system for minimally invasive tumor destruction. This chart shows the overall short position in the therapeutic medical equipment sector, reflecting market skepticism regarding the acceptance of this technology compared to other ablation methods.
Shares shorted by the overall market
IceCure Medical is promoting an innovative tumor-freezing technology. It's promising, but requires investment. This chart shows rising investor fear. At times like these, markets favor proven solutions, while demand for expensive new medical equipment and funding for its developers plummets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ICCM (ICCM)
For IceCure Medical, this oscillator is a true indicator of hope. The company is promoting cryoablation (freezing) technology for cancer treatment. Any positive news from regulators (such as the FDA) or strong clinical trial data triggers a surge in interest, sending the indicator into the overbought zone (above 70). Conversely, delays or unsuccessful trials immediately dampen investor enthusiasm.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ICCM-ICCM&v=1772583138829 "RSI 14 indicator chart for the company's stock ICCM (ICCM)")
RSI 14 Market Segment - Therapeutic medical equipment
IceCure (ICCM) — "freeze" against cancer (Israel). They perform *"cryoablation"* (freezing) — *minimally invasive* "burning" of tumors (breast, kidney) *with ice*. The "Therapeutic medical equipment" (medtech) sector thrives on R&D. RSI_14_Seg shows whether the *entire* sector is "overbought." This helps to distinguish: is ICCM's growth their "icy" niche or a general *overheating"?
RSI 14 for the overall market
IceCure Medical, a manufacturer of cryoablation equipment, sees this chart as a proxy for hospital budgets. During periods of market euphoria and economic growth, hospitals readily invest in expensive technological upgrades. During periods of panic and recession, capital expenditures are frozen, and projects to implement new equipment are postponed.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ICCM (ICCM)
IceCure Medical is an Israeli medical technology company that developed the ProSense system. It uses cryoablation (extreme freezing) to destroy tumors (such as breast cancer) without surgical incision. This chart shows the speculative average price target from analysts, based on their belief in FDA approval and adoption of this technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ICCM-ICCM&v=1772583138878 "A chart showing analyst consensus forecasts for the expected stock price. ICCM (ICCM)")
The difference between the consensus estimate and the actual stock price ICCM (ICCM)
IceCure Medical (ICCM) is an Israeli medical technology company that uses cryoablation (freezing) to destroy tumors (breast and kidney) without surgery. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting whether analysts believe their "ice" technology (ProSense) will become a standard of care.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ICCM-ICCM&v=1772583138900 "A chart showing the difference between the consensus forecast and the actual stock price. ICCM (ICCM)")
Analyst consensus forecast for stock prices by market segment - Therapeutic medical equipment
IceCure Medical is an Israeli company that developed cryoablation (freezing)—a minimally invasive method for destroying tumors (especially breast cancer) without surgery. This chart shows general expectations for the therapeutic medical device sector. It reflects whether experts believe in this alternative to lumpectomy.
Analysts' consensus forecast for the overall market share price
IceCure Medical is an Israeli company that has developed cryoablation (freezing) technology for destroying tumors (breast and kidney cancer) without surgery. This chart shows overall market sentiment. For IceCure, a company with innovative medical technology, the overall optimism is important because it reflects hospitals' willingness to invest in new equipment.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ICCM
IceCure Medical is an Israeli medtech company that freezes cancer. Their technology (ProSense) is cryoablation: they use an ultra-cold probe to destroy tumors (breast, kidney, lung) minimally invasively. This graph summarizes their commercialization. It reflects their R&D progress, their quest for FDA approval, and their chances of making ice ball therapy a surgical alternative.
AKIMA Market Segment Index - Therapeutic medical equipment
IceCure Medical (ICCM) has developed cryoablation technology (extreme cold treatment) for tumor destruction. Their ProSense system is used to treat breast, kidney, and lung cancer. The graph shows the average index for the segment, allowing one to assess how this innovative medical technology compares to the average in the competitive therapeutic equipment sector.
The AKIM Index for the overall market
IceCure Medical is an Israeli company that developed ProSense, a tumor cryoablation (freezing) technology. It's an alternative to surgery. This chart, reflecting the market average, is just a backdrop. It helps assess how this MedTech story, which promotes minimally invasive cancer treatment, stacks up against overall macroeconomic trends.
